Replies to post #457038 on Anavex Life Sciences Corp (AVXL)

[boi568]

I don't know how you come to your conclusions about the Anavex trials.

1. The AD trial prospects are looking better than ever, given (1) the CHMP go ahead for filing an MAA; and, (2) the draft FDA guidance pretty much obviating the need for an ADL endpoint win, validating Kun Jin's .025 ADAS-Cog/CDR-SB choice.

2. The Rett trial was not a drug fail; it was a trial design fail. Not good, of course, but not at all a repudiation of 2-73's efficacy in this indication.

3. As for schizo, we are dealing with a 3-71 trial.

Whatever your perception of other people's perception, the Anavex clinical program is very much alive, with a solid cash position for the upcoming AD regulatory season.